Neurosarcoidosis-like reaction under TNF-α inhibitors: a case report and literature review of a paradoxical immune phenomenon
Open Access
- 16 March 2026
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (4)
Abstract
Background: Neurosarcoidosis (NS) is a rare manifestation of sarcoidosis that oftenrequires long-term immunosuppressive treatment (IST), including tumor necrosis factor-α (TNF-α) inhibitors in refractory cases. Paradoxically, TNF-α blockade has also been associated withsarcoidosis-like reactions (SLRs), granulomatous inflammatory conditions that mimic idiopathicsarcoidosis. Case presentation: We report a case of NS occurring in the context of a TNF-αinhibitor–associated SLR and review previously reported cases during TNF-α inhibitor therapy. Discussion: A 25- year-old man with HLA-B27–negative ankylosing spondylitis developed anacute central nervous system (CNS) inflammatory syndrome during prolonged adalimumabtherapy. The diagnosis was supported by inflammatory cerebrospinal fluid (CSF) findings,including an elevated CD4+/CD8+ ratio, histologically confirmed pulmonary SLR, and sustainedradiological and neurological remission after adalimumab withdrawal. A review of the literatureidentified only seven reported cases of NS during anti-TNF-α therapy across heterogeneousimmune-mediated inflammatory diseases. Clinical and neuroimaging features were variable,whereas CSF analysis consistently showed inflammatory changes. Exposure duration prior toneurological onset and follow-up strategies were inconsistently reported, and acute IST wasfrequently required because of CNS involvement. Conclusions: This case expands the clinicalspectrum of anti-TNF-α– associated SLRs and underscores the importance of considering aniatrogenic etiology in paradoxical neuroinflammatory presentations. Recognition of a“neurosarcoidosis-like reaction” may inform long-term therapeutic decisions, including carefulconsideration of TNF-α inhibitor re-exposure and selection of alternative ISTs for the underlyingdisease.Keywords
Funding Information
- Università degli Studi di Ferrara
This publication has 28 references indexed in Scilit:
- A case of neurosarcoidosis secondary to treatment of etanercept and review of the literatureBMJ Case Reports, 2015
- The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.2014
- Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritisBMC Neurology, 2013
- Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitorsJournal of Neurology, 2013
- Dual role of anti-TNF therapy: Enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissuesClinical Immunology, 2011
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune DiseasesImmunity, 2009
- Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab.2007
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- Treatment with monoclonal anti-tumor necrosis factor ? antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritisArthritis & Rheumatism, 1999
- Cells and cytokines involved in the pathogenesis of sarcoidosis.1999